Full text is available at the source.
Abstract
A total of 7,458 participants were included in each group, with a mean eGFR of 23-24 mL/min/1.73 m².
- New users of GLP-1 RAs had a higher risk for major adverse kidney events (HR 1.05) and dialysis (HR 1.09) compared to SGLT2i users.
- No significant difference in all-cause mortality (HR 0.98) and major adverse cardiovascular events (HR 0.97) was observed between the two groups.
- GLP-1 RA users had a lower risk for heart failure (HR 0.94) compared to those on SGLT2i.
- Among GLP-1 RA users, higher risks for adverse kidney events were noted in males and in patients without heart failure.
- Initiating an SGLT2i may be associated with a lower risk of adverse kidney events in patients with type 2 diabetes and stage 4-5 chronic kidney disease.
Simplified